NEW YORK, May 4, 2017 /PRNewswire/ --
Stock-Callers.com directs investors' attention to these Drug Manufacturers equities: Teva Pharmaceutical Industries Ltd (NYSE:
TEVA), Endo International PLC (NASDAQ: ENDP), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Amarin Corp. PLC (NASDAQ: AMRN).
Pharmaceutical Manufacturing industry companies manufacture and process pharmaceutical products, and their profitability depends
on their ability to discover and market new drugs. You can access our complimentary research reports on these stocks now at:
http://stock-callers.com/registration
Teva Pharma
Shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd saw a drop of
4.33%, ending Wednesday's trading session at $30.72. The stock recorded a trading volume of 11.45
million shares, which was higher than its three months average volume of 8.15 million shares. The Company's shares are trading
6.68% below their 50-day moving average. Moreover, shares of Teva Pharma, which develops, manufactures, markets, and distributes
generic medicines and a portfolio of specialty medicines worldwide, have a Relative Strength Index (RSI) of 39.32.
On April 27 th, 2017, Teva Pharma announced the publication of results from the Phase
II/III study ARM-TD (Aim to Reduce Movements in Tardive Dyskinesia) in Neurology®, the
medical journal of the American Academy of Neurology. The ARM-TD study evaluated the safety and efficacy of the
investigational use of deutetrabenazine (SD-809) compared to placebo in the treatment of moderate to severe tardive dyskinesia.
Visit us today and download your complete report on TEVA for free at:
http://stock-callers.com/registration/?symbol=TEVA
Endo
Dublin, Ireland headquartered Endo International PLC's stock dropped 6.52%, closing the day
at $10.89 with a total trading volume of 6.87 million shares. The Company's shares are trading
2.93% below their 50-day moving average. Shares of the Company, which develops, manufactures, and distributes pharmaceutical
products and devices worldwide, have an RSI of 47.05.
On May 01 st, 2017, Endo International announced that Paul
Campanelli, President and CEO, is scheduled to present at the UBS Global Healthcare Conference in New York on Tuesday, May 23 rd, 2017, at 8:00 a.m. ET. A live webcast and audio archive of the event will be available on the Company's website. The
complimentary research report on ENDP can be accessed at:
http://stock-callers.com/registration/?symbol=ENDP
Ionis Pharma
On Wednesday, shares in Carlsbad, California headquartered Ionis Pharmaceuticals Inc.
recorded a trading volume of 752,229 shares. The stock ended the day 1.12% higher at $47.97. The
Company's shares have advanced 24.76% in the past month, 8.06% in the previous three months, and 0.29% on an YTD basis. The stock
is trading above its 50-day and 200-day moving averages by 10.98% and 21.05%, respectively. Furthermore, shares of Ionis Pharma,
which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 62.32.
On April 26 th, 2017, Ionis Pharma announced that it will host a live webcast on
Tuesday, May 09 th, 2017, at 11:30 a.m. ET to discuss its
Q1 2017 financial results and report on pipeline and business progress. The webcast may be accessed on the Company's
website. Register for free on Stock-Callers.com and download the PDF research report on IONS at:
http://stock-callers.com/registration/?symbol=IONS
Amarin
Dublin, Ireland-based Amarin Corp. PLC's stock fell 5.05%, finishing yesterday's session at
$3.01. A total volume of 4.54 million shares was traded, which was above their three months average
volume of 1.48 million shares. The Company's shares have advanced 2.03% in the previous three months. The stock is trading below
its 200-day moving average by 2.97%. Additionally, shares of Amarin, which focuses on the development and commercialization of
therapeutics for the treatment of cardiovascular diseases in the US, have an RSI of 32.25. Get free access to your research
report on AMRN at:
http://stock-callers.com/registration/?symbol=AMRN
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES :
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you ' re
a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between
09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA